Former Insys Therapeutics sales manager Jeffrey Pearlman is the latest executive from the company to be indicted in a kickback scheme involving Insys’s cancer pain management drug Subsys (United States v. Pearlman, D. Conn., No. 17-cr-27, indictment 2/8/17).
Pearlman was indicted Feb. 8 on one count of conspiracy to violate the anti-kickback law through his management of a sham speaker marketing program promoting Subsys. The speaker series was ostensibly an educational outreach effort for practitioners to educate their peers on Subsys, but federal prosecutors from the U.S. Attorney’s Office for the District of Connecticut alleged that the events ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.